A Phase 3 interventional study of Pelacarsen (TQJ230) 80 mg s.c. and Corresponding Placebo in Hyperlipoproteinemia(a), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.
Lipoprotein apheresis to date is the only approved therapeutic option for cardiovascular (CV) risk reduction in patients with severely elevated Lp(a) levels in Germany. Lipoprotein apheresis is an expensive, burdensome, and time-consuming procedure. The current study (CTQJ230A12302) investigated if treatment with pelacarsen (TQJ230) 80 mg Q4W vs placebo reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia(a) and established CV disease
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 51 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pelacarsen (TQJ230) 80 mg s.c. Q4W
Drug: Pelacarsen (TQJ230) 80 mg s.c.
Placebo to Pelacarsen s.c. Q4W
Drug: Corresponding Placebo
Pelacarsen (TQJ230) 80 mg s.c. Q4W
Also known as: TQJ230
Placebo to Pelacarsen
Also known as: Placebo
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early. This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions. Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.
Time frame: Up to Week 52
Time to Lipoprotein Apheresis Avoidance
Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.
Time frame: From randomization up to Week 52
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52
Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.
Time frame: Week 12 up to Week 52
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
Time frame: Baseline, week 52
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
Time frame: Baseline, week 52
Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule
Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52. Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.
Time frame: Week 12 to 52, Week 24 to 52
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52
Number of participants with no apheresis performed between week 24 to week 52.
Time frame: Week 24 to Week 52
Time-averaged Lp(a) Levels Reported as mg/dL
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
Time frame: Baseline, Week 52
Time-averaged Lp(a) Levels Reported as Nmol/L
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
Time frame: Baseline, Week 52
Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52
Evaluate the change in expanded lipid profile parameters measured in mg/dL
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 52
Patient Preference Questionnaire
Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection. The number of participants that prefer each option at baseline and 52 weeks is reported.
Time frame: Baseline, Week 52
A total of 51 participants were recruited in 13 centers across Germany
| Milestone | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Started | 26 | 25 |
| Completed | 25 | 23 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early. This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions. Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.
| Apheresis sessions received per week | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule | 0.16 (0.04 to 0.25) | 0.93 (0.90 to 1.00) |
Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.
| weeks | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Time to Lipoprotein Apheresis Avoidance | 6.14 (3.14 to 10.14) | NA (NA to NA) |
Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.
| Participants | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52 | 18 | 0 |
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
| ratio from baseline | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL | 0.32 (0.26 to 0.39) | 1.11 (0.89 to 1.38) |
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
| ratio from baseline | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L | 0.27 (0.21 to 0.34) | 1.14 (0.89 to 1.45) |
Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52. Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.
| Apheresis session per week | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| 12 to 52 weeks - Imputed data | 0.11 (0.00 to 0.10) | 0.93 (0.88 to 1.00) |
| 24 to 52 weeks - Imputed data | 0.10 (0.00 to 0.07) | 0.93 (0.96 to 1.00) |
Number of participants with no apheresis performed between week 24 to week 52.
| Participants | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52 | 19 | 0 |
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
| mg/dL | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Baseline | 75.4 ± 25.98 | 63.2 ± 15.89 |
| Week 52 | 34.2 ± 32.41 | 73.7 ± 19.78 |
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
| nmol/L | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Baseline | 159.9 ± 56.67 | 130.1 ± 34.40 |
| Week 52 | 65.6 ± 68.05 | 156.2 ± 44.60 |
Evaluate the change in expanded lipid profile parameters measured in mg/dL
| percentage change from baseline | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| LDL-C | 3.64 ± 50.490 | 8.85 ± 26.265 |
| Total cholesterol | 6.23 ± 24.810 | 2.37 ± 17.587 |
| HDL-C | 16.93 ± 26.059 | -2.31 ± 13.465 |
| Non-HDL-C | 1.82 ± 42.291 | 6.97 ± 22.968 |
| VLDL-C | 2.01 ± 40.267 | 5.31 ± 42.146 |
| Triglycerides | 31.60 ± 95.892 | 5.08 ± 18.62 |
| Apo-B | 0.95 ± 36.488 | 6.70 ± 17.652 |
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
| scales on a score | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Baseline | 51.2 ± 8.06 | 48.3 ± 9.02 |
| Week 52 | 49.4 ± 9.44 | 50.3 ± 6.76 |
| Change from baseline to Week 52 | -2.05 ± 6.653 | 0.83 ± 4.554 |
The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
| scales on a score | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Baseline | 53.6 ± 6.78 | 52.6 ± 7.21 |
| Week 52 | 54.8 ± 6.09 | 54.8 ± 6.55 |
| Change from baseline to Week 52 | 1.95 ± 6.436 | 3.67 ± 4.589 |
Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection. The number of participants that prefer each option at baseline and 52 weeks is reported.
| Participants | Pelacarsen (TQJ230) | Placebo |
|---|---|---|
| Baseline - Weekly apheresis | 0 | 0 |
| Baseline - monthly self-injection | 25 | 24 |
| Week 52 - Weekly apheresis | 0 | 0 |
| Week 52 - monthly self-injection | 20 | 19 |
Collected over From baseline to 16 weeks after last treatment up to 68 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pelacarsen | 0/26 (0%) | 7/26 (26.9%) | 23/26 (88.5%) |
| Placebo | 1/25 (4%) | 6/25 (24%) | 17/25 (68%) |
| Total | 1/51 (2%) | 13/51 (25.5%) | 40/51 (78.4%) |
| Event | Pelacarsen | Placebo | Total |
|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/26 | 1/25 | 1/51 |
| Coronary artery diseaseCardiac disorders | 0/26 | 1/25 | 1/51 |
| GastritisGastrointestinal disorders | 0/26 | 1/25 | 1/51 |
| Large intestine polypGastrointestinal disorders | 0/26 | 1/25 | 1/51 |
| PneumoniaInfections and infestations | 0/26 | 1/25 | 1/51 |
| Rib fractureInjury, poisoning and procedural complications | 0/26 | 1/25 | 1/51 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/26 | 1/25 | 1/51 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/26 | 1/25 | 1/51 |
| SyncopeNervous system disorders | 1/26 | 1/25 | 2/51 |
| Myocardial infarctionCardiac disorders | 1/26 | 0/25 | 1/51 |
| Event | Pelacarsen | Placebo | Total |
|---|---|---|---|
| Injection site erythemaGeneral disorders and administration site conditions | 10/26 | 0/25 | 10/51 |
| NasopharyngitisInfections and infestations | 6/26 | 9/25 | 15/51 |
| COVID-19Infections and infestations | 6/26 | 5/25 | 11/51 |
| HeadacheNervous system disorders | 6/26 | 0/25 | 6/51 |
| Iron deficiencyMetabolism and nutrition disorders | 2/26 | 5/25 | 7/51 |
| FatigueGeneral disorders and administration site conditions | 5/26 | 1/25 | 6/51 |
| Respiratory tract infectionInfections and infestations | 5/26 | 0/25 | 5/51 |
| Injection site pruritusGeneral disorders and administration site conditions | 4/26 | 1/25 | 5/51 |
| Back painMusculoskeletal and connective tissue disorders | 4/26 | 2/25 | 6/51 |
| Influenza like illnessGeneral disorders and administration site conditions | 3/26 | 0/25 | 3/51 |
| Age, Categorical(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 15 | 30 |
| >=65 years | 11 | 10 | 21 |
| Age, Continuous(years) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Mean | 62.0 ± 8.10 | 61.4 ± 9.35 | 61.7 ± 8.65 |
| Sex: Female, Male(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 20 | 19 | 39 |
| Race/Ethnicity, Customized(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Race — White | 26 | 25 | 51 |
| Race/Ethnicity, Customized(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Ethnicity — Not hispanic or latino | 26 | 25 | 51 |
| Participants with prior clinically significant symptomatic coronary artery disease(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Count of participants | 1 | 3 | 4 |
| Participants with prior miocardial infarction(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Count of participants | 21 | 19 | 40 |
| Participants with prior ischemic stroke(Participants) | Pelacarsen (TQJ230) | Placebo | Total |
|---|---|---|---|
| Count of participants | 1 | 5 | 6 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2022 to primary completion in Jan 2025, 29 months.
Results were first posted in Jul 2026, 1 year 5 months after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 29 months is below that.
Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pelacarsen